Class Compound HDAC target Phase Company Condition tested in Clinical Trials
Hydroxamic acid Zolinza, vorinostat (SAHA) Classes I and II FDA Merck Approved for CTCL, phase I/ II for gastric cancer, NSCLC, thyroid cancer and advanced cancers
 Panobinostat (LBH589) Classes I and II III Novartis Phase III trial for CTCL and phase II for CML, MM, NHL, HL, BC, chordoma, prostate and others advanced solid tumors
Belinostat (PXD101) Classes I and II II TopoTarget Relapsed ovarian cancer, TCL, thymoma, thymic carcinoma, MM, NSCLC, brain tumors
Givinostat or Gavinostat (ITF2357) Classes I and II II Italfarmaco Relapsed leukemias and MM
Trichostatin (TSA) Classes I and II N/C N/C N/C
Abexinostat (PCI-24781) Classes I and II II Pharmacyclics BCL, sarcoma
LAQ-824 Classes I and II I Novartis Solid and hematologic malignancies
Pracinostat  (SB939) Classes I, II and SIRT 1 II MEI Pharma Prostate cancer, solid tumors, hematologic malignancies
JNJ-26481585 HDAC1, HDAC6 I Johnson & Johnson Leukemia, CTCL and solid tumors
CUDC-101 Classes I and II I Curis Head and neck, gastric, BC, liver cancer, MM, NSCLC
CHR-3996 Class I I Chroma Therapeutics Solid tumors
CHR-2845 Class I I Chroma Therapeutics Hematological diseases or lymphoid malignancies
Quisinostat (JNJ 26481585) Class I II MedKoo bioscience CTCL, MM
CG200745 Pan-HDAC I CrystalGenomics, Inc, Solid tumors
Rocilinostat (ACY-1215) HDAC6 I and II MedKoo bioscience MM
Benzamides Entinostat (MS-275 SNDX275) HDAC1,HDAC2,HDAC3 II Schering HL, lung cancer, ALL, BC, melanoma and advanced solid tumors
Mocetinostat (MGCD0103) HDAC1 and HDAC2 II Methylgene AML
Tacedinaline (CI-994) HDAC1 and HDAC2 II and III Parke-Davis Pharmaceutical MM, pancreatic cancer, phase III for Lung Cancer
AR-42 Pan-HDAC I Arno Therapeutics MM, CLL or lymphoma
4SC-202 HDAC1, HDAC2, HDAC3 I MedKoo bioscience Hematological malignancies
Resminostat (4SC-201) Classes I and II I and II MedKoo bioscience Hepatocellular carcinoma , colorectal cancer and HL
Cyclic Peptides Romidepsin/Istodax HDAC1 and HDAC2 FDA Celgene Aproved for CTCL
(FK228 and FR901228)
Aliphatic Acids Valproic Acid Classes I and IIa II and III Abbot Phase III trials for cervical cancer, ovarian cancer and phase II for sarcomas, BC, malignant melanoma, AML, brain tumors and advanced cancers
Phenylbutyrate (PB) Classes I and IIa I and II Targon Corporation Colorectal cancer, malignant gliomas, solid tumors, leukemias, lymphomas
Butyrate Classes I and IIa I, II and III   Lymphoproliferative disorders, prostate cancer or other solid tumors, phase III for ovarian cancer
ALL: Acute Lymphoblastic Leukemia; AML: Acute Myeloid Leukemia; BCL: B-Cell Lymphoma; CLL: Chronic Lymphocytic Leukemia; CML: Chronic Myeloid Leukemia; CTCL: Cutaneous T Cell Lymphoma; HL: Hodgkin Lymphoma; MM: Multiple Myeloma; N/A: not available; NHL: Non-Hodgkin Lymphoma; NSCLC: Non-Small- Cell Lung Carcinoma; TCLT: T Cell Lymphoma.
Table 1: Summary of Main HDACi Drugs and Agents in Clinical Trials.